Dimitrios C Mastellos

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5570576/publications.pdf

Version: 2024-02-01

72	7,201	87723 38	88477 70
papers	citations	h-index	g-index

79	79	79	8607
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Complement and tissue factorâ€“enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. Journal of Clinical Investigation, 2020, 130, 6151-6157.	3.9	580
2	Complement as a target in COVID-19?. Nature Reviews Immunology, 2020, 20, 343-344.	10.6	426
3	A Novel C5a Receptor-Tissue Factor Cross-Talk in Neutrophils Links Innate Immunity to Coagulation Pathways. Journal of Immunology, 2006, 177, 4794-4802.	0.4	412
4	The Proinflammatory Mediators C3a and C5a Are Essential for Liver Regeneration. Journal of Experimental Medicine, 2003, 198, 913-923.	4.2	385
5	Novel mechanisms and functions of complement. Nature Immunology, 2017, 18, 1288-1298.	7.0	364
6	Complement component C3 â€“ The â€œSwiss Army Knifeâ€•of innate immunity and host defense. Immunological Reviews, 2016, 274, 33-58.	2.8	313
7	The renaissance of complement therapeutics. Nature Reviews Nephrology, 2018, 14, 26-47.	4.1	305
8	New insights into the immune functions of complement. Nature Reviews Immunology, 2019, 19, 503-516.	10.6	281
9	Complement in cancer: untangling an intricate relationship. Nature Reviews Immunology, 2018, 18, 5-18.	10.6	279
10	Clinical promise of next-generation complement therapeutics. Nature Reviews Drug Discovery, 2019, 18, 707-729.	21.5	253
11	The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clinical Immunology, 2020, 215, 108450.	1.4	252
12	A Novel Role of Complement: Mice Deficient in the Fifth Component of Complement (C5) Exhibit Impaired Liver Regeneration. Journal of Immunology, 2001, 166, 2479-2486.	0.4	220
13	Functional receptor for C3a anaphylatoxin is expressed by normal hematopoietic stem/progenitor cells, and C3a enhances their homing-related responses to SDF-1. Blood, 2003, 101, 3784-3793.	0.6	217
14	Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy. Clinical Immunology, 2020, 220, 108598.	1.4	191
15	Compstatin: a C3â€targeted complement inhibitor reaching its prime for bedside intervention. European Journal of Clinical Investigation, 2015, 45, 423-440.	1.7	178
16	C3a and C3b Activation Products of the Third Component of Complement (C3) Are Critical for Normal Liver Recovery after Toxic Injury. Journal of Immunology, 2004, 173, 747-754.	0.4	155
17	Protection of innate immunity by C5aR antagonist in septic mice. FASEB Journal, 2002, 16, 1567-1574.	0.2	152
18	Complement: more than a â€˜guardâ€™ against invading pathogens?. Trends in Immunology, 2002, 23, 485-491.	2.9	144

#	Article	IF	Citations
19	Increased C5a receptor expression in sepsis. Journal of Clinical Investigation, 2002, 110, 101-108.	3.9	141
20	Phylogenetic aspects of the complement system. Developmental and Comparative Immunology, 2001, 25, 745-762.	1.0	118
21	In Vivo Role of Complement-Interacting Domains of Herpes Simplex Virus Type 1 Glycoprotein Gc. Journal of Experimental Medicine, 1999, 190, 1637-1646.	4.2	108
22	Complement Component 3 Is Required for Optimal Expansion of CD8 T Cells During a Systemic Viral Infection. Journal of Immunology, 2003, 170, 788-794.	0.4	105
23	Increased C5a receptor expression in sepsis. Journal of Clinical Investigation, 2002, 110, 101-108.	3.9	103
24	Complement C5a Receptor Is Essential for the Optimal Generation of Antiviral CD8+ T Cell Responses. Journal of Immunology, 2004, 173, 2524-2529.	0.4	97
25	Herpes Simplex Virus Type 1 Evades the Effects of Antibody and Complement In Vivo. Journal of Virology, 2002, 76, 9232-9241.	1.5	91
26	Complement-triggered pathways orchestrate regenerative responses throughout phylogenesis. Seminars in Immunology, 2013, 25, 29-38.	2.7	72
27	Complement in Thrombotic Microangiopathies: Unraveling Ariadne's Thread Into the Labyrinth of Complement Therapeutics. Frontiers in Immunology, 2019, 10, 337.	2.2	69
28	Applying complement therapeutics to rare diseases. Clinical Immunology, 2015, 161, 225-240.	1.4	60
29	Complement-Dependent Mechanisms and Interventions in Periodontal Disease. Frontiers in Immunology, 2019, 10, 406.	2.2	60
30	Novel monoclonal antibodies against mouse C3 interfering with complement activation: description of fine specificity and applications to various immunoassays. Molecular Immunology, 2004, 40, 1213-1221.	1.0	57
31	Cloning and purification of the rainbow trout fifth component of complement (C5). Developmental and Comparative Immunology, 2001, 25, 419-430.	1.0	54
32	Complement: Structure, Functions, Evolution, and Viral Molecular Mimicry. Immunologic Research, 2003, 27, 367-386.	1.3	53
33	C5a causes limited, polymorphonuclear cell-independent, mesenteric ischemia/reperfusion-induced injuryâˆ†,â˜†â˜†. Clinical Immunology, 2003, 108, 263-273.	1.4	53
34	Phase IIa clinical trial of complement C3 inhibitor AMY-101 in adults with periodontal inflammation. Journal of Clinical Investigation, 2021, 131, .	3.9	47
35	Complement-mediated clearance of erythrocytes: mechanism and delineation of the regulatory roles of Crry and DAF. Blood, 2002, 100, 4544-4549.	0.6	44
36	Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape. Expert Review of Hematology, 2014, 7, 583-598.	1.0	43

#	Article	IF	Citations
37	Novel biological networks modulated by complement. Clinical Immunology, 2005, 115, 225-235.	1.4	42
38	Safety profile after prolonged C3 inhibition. Clinical Immunology, 2018, 197, 96-106.	1.4	38
39	Therapeutic targeting of the complement system. Nature Reviews Drug Discovery, 2019, , .	21.5	37
40	Targeting complement components C3 and C5 for the retina: Key concepts and lingering questions. Progress in Retinal and Eye Research, 2021, 83, 100936.	7.3	37
41	Complement therapeutics in inflammatory diseases: promising drug candidates for C3â€targeted intervention. Molecular Oral Microbiology, 2016, 31, 3-17.	1.3	36
42	A modular integrated lab-on-a-chip platform for fast and highly efficient sample preparation for foodborne pathogen screening. Sensors and Actuators B: Chemical, 2019, 288, 171-179.	4.0	34
43	3,4-Diaminobenzoic Acid Derivatives as Inhibitors of the Oxytocinase Subfamily of M1 Aminopeptidases with Immune-Regulating Properties. Journal of Medicinal Chemistry, 2015, 58, 1524-1543.	2.9	32
44	Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria. Seminars in Hematology, 2018, 55, 167-175.	1.8	32
45	Complement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery. Trends in Immunology, 2017, 38, 383-394.	2.9	31
46	Compstatins: the dawn of clinical C3-targeted complement inhibition. Trends in Pharmacological Sciences, 2022, 43, 629-640.	4.0	31
47	cDNA cloning and phylogenetic analysis of the sixth complement component in rainbow trout. Molecular Immunology, 2006, 43, 1080-1087.	1.0	30
48	Complement emerges as a masterful regulator of CNS homeostasis, neural synaptic plasticity and cognitive function. Experimental Neurology, 2014, 261, 469-474.	2.0	30
49	From discovery to approval: A brief history of the compstatin family of complement C3 inhibitors. Clinical Immunology, 2022, 235, 108785.	1.4	30
50	C3-targeted therapy in periodontal disease: moving closer to the clinic. Trends in Immunology, 2021, 42, 856-864.	2.9	27
51	Is complement the culprit behind COVID-19 vaccine-related adverse reactions?. Journal of Clinical Investigation, 2021, 131, .	3.9	25
52	Complement: An Inflammatory Pathway Fulfilling Multiple Roles at the Interface of Innate Immunity and Development. Inflammation and Allergy: Drug Targets, 2005, 4, 125-127.	3.1	24
53	Bactericidal Action of Smooth and Plasma Microâ€Nanotextured Polymeric Surfaces with Varying Wettability, Enhanced by Incorporation of a Biocidal Agent. Macromolecular Materials and Engineering, 2021, 306, 2000694.	1.7	20
54	Enhanced antibacterial activity of ZnO-PMMA nanocomposites by selective plasma etching in atmospheric pressure. Micro and Nano Engineering, 2021, 13, 100098.	1.4	17

#	Article	IF	Citations
55	Prolonged intraocular residence and retinal tissue distribution of a fourth-generation compstatin-based C3 inhibitor in non-human primates. Clinical Immunology, 2020, 214, 108391.	1.4	16
56	From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage. Immunobiology, 2016, 221, 1046-1057.	0.8	14
57	Taming hemodialysis-induced inflammation: Are complement C3 inhibitors a viable option?. Clinical Immunology, 2019, 198, 102-105.	1.4	11
58	Isothermal Recombinase Polymerase Amplification (RPA) of E. coli gDNA in Commercially Fabricated PCB-Based Microfluidic Platforms. Micromachines, 2021, 12, 1387.	1.4	11
59	From atoms to systems: a cross-disciplinary approach to complement-mediated functions*1. Molecular Immunology, 2004, 41, 153-164.	1.0	10
60	Attenuation of Staphylococcus aureusâ€“Induced Bacteremia by Human Mini-Antibodies Targeting the Complement Inhibitory Protein Efb. Journal of Immunology, 2015, 195, 3946-3958.	0.4	9
61	C3-targeted host-modulation approaches to oral inflammatory conditions. Seminars in Immunology, 2022, 59, 101608.	2.7	9
62	â€˜Stealthâ€™ corporate innovation: an emerging threat for therapeutic drug development. Nature Immunology, 2019, 20, 1409-1413.	7.0	7
63	Efficacy matters: broadening complement inhibition in COVID-19. Lancet Rheumatology, The, 2021, 3, e95.	2.2	6
64	Editorial: Therapeutic Modulation of the Complement System: Clinical Indications and Emerging Drug Leads. Frontiers in Immunology, 2019, 10, 3029.	2.2	6
65	Emerging opportunities for C3 inhibition in the eye. Seminars in Immunology, 2022, 59, 101633.	2.7	5
66	Inducing and Characterizing Liver Regeneration in Mice: Reliable Models, Essential â€œReadoutsâ€•and Critical Perspectives. Current Protocols in Mouse Biology, 2013, 3, 141-170.	1.2	4
67	Complement C5a-Mediated TAM-ing of Antitumor Immunity Drives Squamous Carcinogenesis. Cancer Cell, 2018, 34, 531-533.	7.7	4
68	Cross-Disciplinary Research Stirs New Challenges into the Study of the Structure, Function and Systems Biology of Complement. Advances in Experimental Medicine and Biology, 2006, 586, 1-16.	0.8	4
69	Complement C3 activation in the ICU: Disease and therapy as Bonnie and Clyde. Seminars in Immunology, 2022, 60, 101640.	2.7	2
70	Complement as a target in COVID-19?. , 0, .		1
71	Complement C3 as a Target of Host Modulation in Periodontitis. , 2020, , 13-29.		1
72	Response to â€œComment on Mastellos and colleagues and efficacy of complement-targeting drugs in COVID-19â€• Clinical Immunology, 2021, 222, 108617.	1.4	0